Man Group’s Pliant Therapeutics PLRX Stock Holding History

Man Group’s Portfolio PLRX Stock Details PLRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-11,348	Closed	-$219K	–	2203
2022 Q4	$219K	Sell	11,348 -7,024	-38%	-$147K	﹤0.01%	1737
2022 Q3	$384K	Buy	+18,372	New	+$352K	﹤0.01%	1598

Other funds holding PLRX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TGI

TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

TGI

TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Man Group's PLRX Position: Q1 2023 in Review

Man Group sold out of Pliant Therapeutics (PLRX) in Q1 2023, closing a stake of 11,348 shares — an estimated $219K sold.

Man Group first reported a position in PLRX in Q3 2022 and held it in 2 quarters. The position peaked at $384K in Q3 2022. 143 funds tracked by Wall St. Rank hold PLRX as of Q1 2023.

Man Group reported no remaining Pliant Therapeutics position as of Q1 2023 after selling out during the quarter.
Man Group sold 11,348 Pliant Therapeutics shares in Q1 2023, an estimated $219K.
Man Group first reported a position in Pliant Therapeutics in Q3 2022 and held it in 2 quarters.
Man Group's Pliant Therapeutics position peaked at $384K in Q3 2022.
143 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q1 2023.

Based on Man Group's 13F filing for Q1 2023, filed 15 May 2023.